Crisnatol

Crisnatol (BW-A770U) is an experimental anticancer agent.[1] A Phase I clinical trial was published in 1999.[2]

Crisnatol
Clinical data
ATC code
  • none
Identifiers
  • 2-(Chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H23NO2
Molar mass345.442 g·mol−1
3D model (JSmol)
  • CC(CO)(CO)NCc1cc2c3ccccc3ccc2c4c1cccc4
  • InChI=InChI=1S/C23H23NO2/c1-23(14-25,15-26)24-13-17-12-22-18-7-3-2-6-16(18)10-11-21(22)20-9-5-4-8-19(17)20/h2-12,24-26H,13-15H2,1H3 checkY
  • Key:SBRXTSOCZITGQG-UHFFFAOYSA-N checkY

References
  1. U.S. Patent 4,719,046
  2. Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, et al. (November 1999). "A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies". Clinical Cancer Research. 5 (11): 3369–78. PMID 10589747.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.